RCM
ALXO icon

RA Capital Management’s ALX Oncology ALXO Stock Holding History

RA Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9M Hold
13,011,849
– – 0.23% 57
2026
Q1 		$26.1M Buy
+13,011,849
New +$24.8M 0.28% 51

Other funds holding ALXO

VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RA Capital Management's ALXO Position: Q2 2026 in Review

RA Capital Management held its ALX Oncology (ALXO) position steady in Q2 2026 at 13,011,849 shares worth $26.9M. The position accounts for 0.23% of the portfolio, ranked #57.

RA Capital Management first reported a position in ALXO in Q1 2026 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • RA Capital Management held 13,011,849 shares of ALX Oncology worth $26.9M as of Q2 2026.
  • RA Capital Management left its ALX Oncology share count unchanged in Q2 2026.
  • ALX Oncology made up 0.23% of RA Capital Management's portfolio in Q2 2026, its #57 holding.
  • RA Capital Management first reported a position in ALX Oncology in Q1 2026 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.